Advertisement

Catheter ablation for monomorphic ventricular tachycardia in Brugada syndrome patients: detailed characteristics and long-term follow-up

  • Sayuri TokiokaEmail author
  • Seiji Fukamizu
  • Takeshi Kitamura
  • Satoshi Miyazawa
  • Iwanari Kawamura
  • Rintaro Hojo
  • Harumizu Sakurada
  • Masayasu Hiraoka
Article

Abstract

Purpose

Brugada syndrome (BrS) is a risk of sudden cardiac death due to polymorphic ventricular tachycardia and ventricular fibrillation with unusual monomorphic ventricular tachycardia (MVT). Detailed characteristics of MVT and long-term outcome of catheter ablation are still unknown. This study is aimed to identify the detailed characteristics and long-term follow-up of catheter ablation in BrS patients.

Methods

We evaluated 188 patients who were diagnosed with BrS from March 1999 to March 2018. Of those, patients who developed MVT and underwent catheter ablation were included. We identified eight MVTs in seven BrS patients.

Results

Three of them already had implantable cardioverter-defibrillator, and MVTs were terminated by cardioversion or anti-tachycardia pacing. Four patients presented with MVT originating from the right ventricular outflow tract, one patient had MVT arising from the LV septum, one patient had MVT arising from the tricuspid annulus, and one patient had bundle branch reentry ventricular tachycardia. All MVTs were successfully treated by catheter ablation in the acute phase, and seven of eight (87.5%) were free from ventricular tachyarrhythmia during the long-term follow-up (median, 7.2 years).

Conclusions

All MVT cases were successfully treated by catheter ablation. We observed high ventricular arrhythmia free rate following catheter ablation during the long-term follow-up period. BrS patients who developed MVT should consider catheter ablation.

Keywords

Anti-tachycardia pacing Brugada syndrome Catheter ablation Implantable cardioverter-defibrillator Monomorphic ventricular tachycardia 

Notes

Compliance with ethical standards

This retrospective observational study was approved by the Institutional Review Board of Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Rodriguez-Manero M, Sacher F, de Asmundis C, Maury P, Lambiase PD, Sarkozy A, et al. Monomorphic ventricular tachycardia in patients with Brugada syndrome: a multicenter retrospective study. Heart Rhythm. 2016;13:669–82.CrossRefGoogle Scholar
  2. 2.
    Akbarzadeh M, Haghjoo M. Monomorphic ventricular tachycardia originating from right ventricular outflow tract as a trigger for the recurrent ventricular fibrillation in a patient with Brugada syndrome. Res Cardiovasc Med. 2014;3:e17113.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Ogawa M, Kumagai K, Saku K. Spontaneous right ventricular outflow tract tachycardia in a patient with Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:838–40.CrossRefGoogle Scholar
  4. 4.
    Goto M, Sato M, Kitazawa H, Komatsu Y, Fuse K, Takahashi M, et al. Brugada syndrome combined with monomorphic ventricular tachycardia and atrioventricular nodal reentrant tachycardia. Intern Med. 2015;54:1223–6.CrossRefGoogle Scholar
  5. 5.
    Ueyama T, Shimizu A, Esato M, Yoshiga S, Sawa A, Suzuki S, et al. Pilsicainide-induced Brugada-type ECG and ventricular arrhythmias originating from the left posterior fascicle in a case with Brugada syndrome associated with idiopathic left ventricular tachycardia. Europace. 2008;10:86–90.CrossRefGoogle Scholar
  6. 6.
    Wilde AAM, Antzelevitch C, Borggrefe M, Brugada J, Brugada R, Brugada P, et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Eur Heart J. 2002;23:1648–54.CrossRefGoogle Scholar
  7. 7.
    Antzelevitch C, Brugada P, Borggrefe M, Brugada J, Brugada R, Corrado D, et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation. 2005;111:659–70.CrossRefGoogle Scholar
  8. 8.
    Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10(12):1932–63.CrossRefGoogle Scholar
  9. 9.
    Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Nishizaki M, et al. Clinical characteristics and long-term prognosis of senior patients with Brugada syndrome. JACC Clin Electrophysiol. 2017;3:57–67.CrossRefGoogle Scholar
  10. 10.
    Kitamura T, Fukamizu S, Kawamura I, Hojo R, Aoyama Y, Komiyama K, et al. Long-term efficacy of catheter ablation for paroxysmal atrial fibrillation in patients with Brugada syndrome and an implantable cardioverter-defibrillator to prevent inappropriate shock therapy. Heart Rhythm. 2016;13:1455–9.CrossRefGoogle Scholar
  11. 11.
    Mizusawa Y, Sakurada H, Nishizaki M, Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol. 2006;47:359–64.PubMedGoogle Scholar
  12. 12.
    Hutchinson MD, Gerstenfeld EP, Desjardins B, Bala R, Riley MP, Garcia FC, et al. Endocardial unipolar voltage mapping to detect epicardial VT substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(1):49–55.CrossRefGoogle Scholar
  13. 13.
    Brodie OT, Michowitz Y, Belhassen B. Pharmacological therapy in Brugada syndrome. Arrhythm Electrophysiol Rev. 2018;7:135–42.CrossRefGoogle Scholar
  14. 14.
    Roberts JD, Gollob MH, Young C, Connors SP, Gray C, Wilton SB, et al. Bundle branch re-entrant ventricular tachycardia: novel genetic mechanisms in a life-threatening arrhythmia. JACC Clin Electrophysiol. 2017;3:276–88.CrossRefGoogle Scholar
  15. 15.
    Mazur A, Iakobishvili Z, Kusniec J, Strasberg B. Bundle branch reentrant ventricular tachycardia in a patient with the Brugada electrocardiographic pattern. Ann Noninvasive Electrocardiol. 2003;8:352–5.CrossRefGoogle Scholar
  16. 16.
    Sideris S, Archontakis S, Gatzoulis KA, Anastasakis A, Sotiropoulos I, Arsenos P, et al. The subcutaneous ICD as an alternative to the conventional ICD system: initial experience in Greece and a review of the literature. Hell J Cardiol. 2017;58:4–16.CrossRefGoogle Scholar
  17. 17.
    Kondo Y, Ueda M, Kobayashi Y, Schwab JO. New horizon for infection prevention technology and implantable device. J Arrhythm. 2016;32:297–302.CrossRefGoogle Scholar
  18. 18.
    Nakashima T, Takasugi N, Sahashi Y, Suzuki K, Kubota T, Aoyama T, et al. Ventricular tachycardia sensitive to antitachycardia pacing in a patient with severely symptomatic Brugada syndrome. J Interv Card Electrophysiol. 2018;55:239.  https://doi.org/10.1007/s10840-018-0464-6.CrossRefPubMedGoogle Scholar
  19. 19.
    Bertomeu-Gonzalez V, Ruiz-Granell R, Garcia-Civera R, Morell-Cabedo S, Ferrero A. Syncopal monomorphic ventricular tachycardia with pleomorphism, sensitive to antitachycardia pacing in a patient with Brugada syndrome. Europace. 2006;8:1048–50.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of CardiologyTokyo Metropolitan Hiroo HospitalTokyoJapan
  2. 2.Department of CardiologyTokyo Metropolitan Health and Hospitals Corporation Ohkubo HospitalTokyoJapan
  3. 3.Department of CardiologyTokyo Medical Dental UniversityTokyoJapan

Personalised recommendations